AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 1039
Study 14517188 — intervention group
Group type: COMPARATOR
Intervention: Unpurged high-dose therapy (U)
Number of subjects: 140
Study 14517188 — intervention group
Group type: COMPARATOR
Intervention: Purged high-dose therapy (P)
Number of subjects: 140
Study 14517188 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (C)
Number of subjects: 140
Study 14517188 — intervention group
Group type: COMPARATOR
Intervention: Control (C) vs Unpurged + Purged (U + P)
Number of subjects: 140
Study 11156078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium for buttressing (Peri-Strips Dry; Bio‐Vascular, Inc, Saint Paul, MN)
Number of subjects: 65
Study 11156078 — intervention group
Group type: COMPARATOR
Intervention: Control (without bovine pericardium)
Number of subjects: 65
Study 9094873 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified, cow milk-based infant formula (465 mg Ca and 317 mg P/L)
Number of subjects: 103
Study 9094873 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified infant formula with added calcium glycerophosphate (1800 mg Ca and 1390 mg P/L)
Number of subjects: 103
Study 9094873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and supplemented)
Number of subjects: 103
Study 7524255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES with Mw of 450,000 dalton and MS of 0.7
Number of subjects: 40
Study 7524255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES with Mw of 200,000 dalton and MS of 0.5
Number of subjects: 40
Study 7524255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES with Mw of 200,000 dalton and MS of 0.62
Number of subjects: 40
Study 7524255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES with Mw of 40,000 dalton and MS of 0.5
Number of subjects: 40
Study 7524255 — intervention group
Group type: COMPARATOR
Intervention: Control group without ANH (10 patients)
Number of subjects: 40
Study 2685988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 22
Study 2685988 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 22
Study 1098751 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (0.05 ml/kg)
Number of subjects: 200
Study 1098751 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 200
Study 30342394 — intervention group
Group type: EXPERIMENTAL
Intervention: FLZ tablets, administered orally, dosage not specified, duration not specified
Number of subjects: 0
Study 29164255 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter
Number of subjects: 146
Study 29164255 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 146
Study 25960085 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole plus mexiletine 300 mg
Number of subjects: 60
Study 25960085 — intervention group
Group type: COMPARATOR
Intervention: riluzole 100 mg
Number of subjects: 60
Study 23608562 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial education program (PSEP)
Number of subjects: 4295
Study 23608562 — intervention group
Group type: COMPARATOR
Intervention: Not receiving psychosocial education
Number of subjects: 4295
Study 23013045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pennebaker's emotional writing intervention
Number of subjects: 202
Study 23013045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study 19607949 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IVV) with 1 million units (Mu) of alpha interferon
Number of subjects: 0
Study 19607949 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IVV) with 10 million units (Mu) of alpha interferon
Number of subjects: 0
Study 19607949 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (IVV) alone
Number of subjects: 0
Study 17885853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ciclesonide 200 micro g once daily
Number of subjects: 150
Study 17885853 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate-salmeterol (FP-SAL) 500 to 50 micro g twice daily
Number of subjects: 150
Study 17885853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg single dose
Number of subjects: 150
Study 15236630 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxil (500 mg capsule)
Number of subjects: 24
Study 15236630 — intervention group
Group type: COMPARATOR
Intervention: Ultracef (500 mg capsule)
Number of subjects: 24
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days.
Number of subjects: 223
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup aged 35-55.
Number of subjects: 223
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup aged 56-75.
Number of subjects: 223
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup aged over 75.
Number of subjects: 223
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup with early TMS treatment.
Number of subjects: 223
Study 12133499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup with TMS beginning 3 months after onset.
Number of subjects: 223
Study 12133499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMS), basic treatment same as TMS group.
Number of subjects: 223
Study 9822239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% fluorometholone eyedrops four times daily before and after argon laser trabeculoplasty
Number of subjects: 27
Study 9822239 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops four times daily before and after argon laser trabeculoplasty
Number of subjects: 27
Study 7484996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bile acid therapy (chenodeoxycholic acid 500 mg/day and ursodeoxycholic acid 500 mg/day)
Number of subjects: 104
Study 7484996 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone (1000 mg/day)
Number of subjects: 104
Study 7484996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bile acid therapy
Number of subjects: 104
Study 7484996 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone
Number of subjects: 104
Study 2143369 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 27
Study 2143369 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 27
Study 2143369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 27
Study 7443776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium salts
Number of subjects: 17
Study 7443776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium salts with concomitant antidepressive medication (moderate doses for 4 weeks)
Number of subjects: 17
Study 7443776 — intervention group
Group type: COMPARATOR
Intervention: Only lithium
Number of subjects: 17
Study 31782181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) - 0.5g/kg on day 1, 1g/kg on day 2, 0.6g/kg on weeks 3 and 5
Number of subjects: 17
Study 31782181 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched intravenous normal saline (placebo)
Number of subjects: 17
Study 31782181 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label IVIG arm
Number of subjects: 17
Study 30730546 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1416
Study 30730546 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1416
Study 28562678 — intervention group
Group type: EXPERIMENTAL
Intervention: Default option (200g of pre-portioned vegetables)
Number of subjects: 88
Study 28562678 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming (leafy environment with green plants and odour of herbs)
Number of subjects: 88
Study 28562678 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived variety (dividing pre-mixed salad into components)
Number of subjects: 88
Study 26057085 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide bleaching agent
Number of subjects: 31
Study 26057085 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide bleaching agent
Number of subjects: 31
Study 24037762 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized joint hypermobility (GJH)
Number of subjects: 75
Study 20720454 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA lanolin
Number of subjects: 84
Study 20720454 — intervention group
Group type: COMPARATOR
Intervention: Expressed breastmilk (EBM)
Number of subjects: 84
Study 19362318 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration after primary percutaneous coronary intervention (PCI)
Number of subjects: 933
Study 16390282 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructive worry intervention (recording possible solutions to worries)
Number of subjects: 33
Study 16390282 — intervention group
Group type: COMPARATOR
Intervention: Worry group (recording worries and completing worry questionnaires)
Number of subjects: 33
Study 12734132 — intervention group
Group type: EXPERIMENTAL
Intervention: EBT results with Intensive Case Management (ICM) (n = 111)
Number of subjects: 450
Study 12734132 — intervention group
Group type: EXPERIMENTAL
Intervention: EBT results with Usual Care (n = 119)
Number of subjects: 450
Study 12734132 — intervention group
Group type: COMPARATOR
Intervention: EBT results withheld with Intensive Case Management (ICM) (n = 124)
Number of subjects: 450
Study 12734132 — intervention group
Group type: COMPARATOR
Intervention: EBT results withheld with Usual Care (n = 96)
Number of subjects: 450
Study 10682290 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal-model theory
Number of subjects: 0
Study 10682290 — intervention group
Group type: COMPARATOR
Intervention: Associative theories
Number of subjects: 0
Study 1793675 — intervention group
Group type: EXPERIMENTAL
Intervention: oral oestradiol valerate in a cyclical combination with cyproterone acetate (n = 19)
Number of subjects: 36
Study 1793675 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 17)
Number of subjects: 36
Study 6422478 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg fenoprofen calcium 3-times daily
Number of subjects: 77
Study 6422478 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen sodium 3-times daily
Number of subjects: 77
Study 30273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation factors method
Number of subjects: 0
Study 30273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Incrementing method
Number of subjects: 0
Study 30273507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonferroni correction method
Number of subjects: 0
Study 28735036 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive Care (proactive outreach plus connection to smoking cessation services)
Number of subjects: 5123
Study 28735036 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 5123
Study 27091525 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log10(AHI+1)
Number of subjects: 601
Study 27091525 — intervention group
Group type: EXPERIMENTAL
Intervention: SaO2 desaturation indices
Number of subjects: 601
Study 24621960 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline (10 g)
Number of subjects: 10
Study 24621960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (L-alanine)
Number of subjects: 10
Study 22504052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection advice delivered orally during a doctor's consultation (Group 2)
Number of subjects: 213
Study 22504052 — intervention group
Group type: COMPARATOR
Intervention: Sun protection advice delivered in letter-form (Group 1)
Number of subjects: 213
Study 19943985 — intervention group
Group type: EXPERIMENTAL
Intervention: High meal frequency (3 meals + 3 snacks/d)
Number of subjects: 16
Study 19943985 — intervention group
Group type: COMPARATOR
Intervention: Low meal frequency (3 meals/d)
Number of subjects: 16
Study 19943985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high MF and low MF)
Number of subjects: 16
Study 18598834 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy (TWT)
Number of subjects: 143
Study 18598834 — intervention group
Group type: COMPARATOR
Intervention: Ligasure tonsillectomy (LT)
Number of subjects: 143
Study 15763437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (8 g/day for 6 weeks)
Number of subjects: 40
Study 15763437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12188054 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal self-management coach
Number of subjects: 160
Study 12188054 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 160
Study 12188054 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal self-management coach and support intervention
Number of subjects: 160
Study 12188054 — intervention group
Group type: COMPARATOR
Intervention: Diabetes information only
Number of subjects: 160
Study 10483898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala‐Gln (Dipeptiven, 0.50 g/kg per day)
Number of subjects: 120
Study 10483898 — intervention group
Group type: COMPARATOR
Intervention: Control group (isonitrogenous and isocaloric PN)
Number of subjects: 120
Study 8743406 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg naproxen
Number of subjects: 28
Study 8743406 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 28
Study 8743406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of naproxen
Number of subjects: 28
Study 8743406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of naproxen
Number of subjects: 28
Study 8743406 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (general)
Number of subjects: 28
Study 1686440 — intervention group
Group type: EXPERIMENTAL
Intervention: NAAXIA (Na+ salt of N-acetyl-aspartylglutamic acid)
Number of subjects: 0
Study 1686440 — intervention group
Group type: COMPARATOR
Intervention: Previous formula (Mg++ salt of N-acetyl-aspartylglutamic acid)
Number of subjects: 0
Study 6435085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 46
Study 6435085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Theo-Dur)
Number of subjects: 46
Study 6435085 — intervention group
Group type: COMPARATOR
Intervention: Placebo for cromolyn
Number of subjects: 46
Study 6435085 — intervention group
Group type: COMPARATOR
Intervention: Placebo for theophylline
Number of subjects: 46
Study 30136743 — intervention group
Group type: COMPARATOR
Intervention: Doll Therapy (DT)
Number of subjects: 30
Study 30136743 — intervention group
Group type: COMPARATOR
Intervention: Gesture-Verbal Treatment (GVT)
Number of subjects: 30
Study 30413519 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based problem-solving therapy (PST) and behavioural activation (BA) apps (Kaiketsu-App and Genki-App) plus treatment as usual (TAU)
Number of subjects: 0
Study 30413519 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control with treatment as usual (TAU) alone
Number of subjects: 0
Study 26856215 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-low potassium target (nLP group, 4.0 mmol/L)
Number of subjects: 910
Study 26856215 — intervention group
Group type: COMPARATOR
Intervention: Normal-high potassium target (nHP group, 4.5 mmol/L)
Number of subjects: 910
Study 25417401 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC) treatment group
Number of subjects: 300
Study 25417401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 23176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial techniques (suboccipital muscle release, fourth intracranial ventricle compression, deep cervical fascia release)
Number of subjects: 39
Study 23176374 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 39
Study 21958494 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (20 mg/kg q12h or q8h depending on age)
Number of subjects: 550
Study 21958494 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (ampicillin + gentamicin or cefotaxime + gentamicin)
Number of subjects: 550
Study 18431478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxycillin (31-54 mg/Kg/day, in three divided doses for three days)
Number of subjects: 1671
Study 18431478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1671
Study 16645974 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based method for measuring joint space width
Number of subjects: 129
Study 16645974 — intervention group
Group type: COMPARATOR
Intervention: Sharp joint space narrowing (JSN) subscale
Number of subjects: 129
Study 16645974 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-to-noise ratio for computer-based method
Number of subjects: 129
Study 16191242 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine at a standard daily dose of 10 mg b.i.d.
Number of subjects: 900
Study 16191242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 10798610 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs) - fish oil extract (EPA 3.2 g, DHA 2.4 g)
Number of subjects: 18
Study 10798610 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control)
Number of subjects: 18
Study 8689472 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and reattribution training
Number of subjects: 442
Study 8689472 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 442
Study 8689472 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytical group therapy
Number of subjects: 442
Study 1686811 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine (60 mg, oral)
Number of subjects: 14
Study 1686811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6414339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 24
Study 6414339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms/kg
Number of subjects: 24
Study 6414339 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 31668850 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (oral exemestane 25 mg per day for 28 days, oral palbociclib 125 mg per day for 21 days every 4 weeks, plus leuprolide 3·75 mg subcutaneously every 4 weeks)
Number of subjects: 184
Study 31668850 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks)
Number of subjects: 184
Study 30373597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention youth
Number of subjects: 534
Study 30373597 — intervention group
Group type: EXPERIMENTAL
Intervention: Older intervention youth
Number of subjects: 534
Study 30373597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 534
Study 27634549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer@Work intervention
Number of subjects: 0
Study 27634549 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 24598375 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational physician condition (screening, feedback, and referral to the occupational physician)
Number of subjects: 617
Study 24598375 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mental health condition (screening, feedback, and referral to e-mental health)
Number of subjects: 617
Study 24598375 — intervention group
Group type: COMPARATOR
Intervention: Control condition (online screening without feedback)
Number of subjects: 617
Study 24598375 — intervention group
Group type: COMPARATOR
Intervention: Occupational physician condition vs Control condition
Number of subjects: 617
Study 24598375 — intervention group
Group type: COMPARATOR
Intervention: e-mental health condition vs Control condition
Number of subjects: 617
Study 22322821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback system using hemodiafiltration with online regeneration of ultrafiltrate (HFR) in isonatric mode
Number of subjects: 0
Study 22322821 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (implied control)
Number of subjects: 0
Study 20180717 — intervention group
Group type: EXPERIMENTAL
Intervention: Artelon CMC spacer (test, n = 72)
Number of subjects: 109
Study 20180717 — intervention group
Group type: COMPARATOR
Intervention: Tendon interposition arthroplasty (control, n = 37)
Number of subjects: 109
Study 20180717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 17616331 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment (n=24)
Number of subjects: 223
Study 17616331 — intervention group
Group type: COMPARATOR
Intervention: HIV treatment only (n=115)
Number of subjects: 223
Study 15832066 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure cognitive behaviour therapy (CBT) via FearFighter (FF)
Number of subjects: 68
Study 15832066 — intervention group
Group type: COMPARATOR
Intervention: Minimal CBT without exposure via Managing Anxiety (MA)
Number of subjects: 68
Study 12504203 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (left hemisphere lesion)
Number of subjects: 56
Study 12504203 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (right hemisphere lesion)
Number of subjects: 56
Study 12504203 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (ipsilateral to brain lesion handedness)
Number of subjects: 56
Study 12504203 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital hemiparesis (contralateral to lesion handedness)
Number of subjects: 56
Study 12504203 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 56